| 邢孔玲,周 平,高 翔,等.放疗联合免疫治疗在鼻咽癌中的研究进展[J].肿瘤学杂志,2025,31(7):633-640. |
| 放疗联合免疫治疗在鼻咽癌中的研究进展 |
| Research Progress on Radiotherapy Combined with Immunotherapy in Nasopharyngeal Carcinoma |
| 投稿时间：2024-11-15 |
| DOI：10.11735/j.issn.1671-170X.2025.07.B010 |
|
 |
| 中文关键词: 鼻咽肿瘤 放射疗法 免疫疗法 疗效 |
| 英文关键词:nasopharyngeal neoplasms radiotherapy immunotherapy efficacy |
| 基金项目:国家自然科学基金（82260474，82303935）；海南省科学技术厅重点研发计划（ZDYF2022SHFZ132，ZDYF2024SHFZ045） |
|
| 摘要点击次数: 269 |
| 全文下载次数: 136 |
| 中文摘要: |
| 摘 要：鼻咽癌是一种源自鼻咽部的恶性肿瘤，因其早期症状较为隐匿，约70%患者在确诊时已处于局部晚期或转移阶段。放射治疗（放疗）是鼻咽癌的主要治疗手段，但单独放疗在局部晚期鼻咽癌患者中的疗效有限，且无法克服肿瘤的耐药性和复发问题。免疫治疗，尤其是免疫检查点抑制剂的引入，为鼻咽癌治疗带来了新的希望。放疗与免疫治疗联合应用在临床中取得了一定的疗效，但仍面临若干挑战。全文综述放疗联合免疫治疗的机制以及在鼻咽癌中的研究进展，包括免疫治疗的介入时机、不同免疫治疗药物及组合，以及放疗的剂量和分割模式的优化。如何在放疗联合免疫治疗中更好地增强机体的抗肿瘤免疫反应，提高治疗效果的同时减轻毒副作用，是未来值得深入探索的方向。 |
| 英文摘要: |
| Abstract： Nasopharyngeal carcinoma(NPC) is a malignant tumor originating from the nasopharyngeal region. Due to the subtle early symptoms， approximately 70% of patients are diagnosed at a locally advanced or metastatic stage. Radiotherapy is the primary treatment modality for NPC， however， its efficacy is limited in patients with locally advanced disease， and it cannot overcome tumor resistance and recurrence issues. The introduction of immunotherapy， particularly immune checkpoint inhibitors， has brought new hope for the treatment of NPC. The combination of radiotherapy with immunotherapy has shown certain clinical efficacy， but several challenges remain. This paper reviews the research progress on the combination of radiotherapy with immunotherapy for NPC patients， including the therapeutic mechanisms， the timing of immunotherapy intervention， the application of different immunotherapy agents and combinations， and the optimization of radiotherapy dose and fractionation schedules. Enhancing the body’s anti?鄄tumor immune response while minimizing toxic side effects in the context of combined radiotherapy and immunotherapy is an area that warrants further investigation in the future. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |